The promise of clinicogenomic data for breakthrough cancer drug development
Life science companies have many different data types at their disposal to support research and development, from established literature and clinical trial evidence to a growing range of real-world data (RWD) assets that are opening up new opportunities every day. Among these novel datasets is clinicogenomic data: a mashup of longitudinal, deidentified clinical information with […]
Breaking through the barriers to expand real-world data use across pharma
Pharma companies are engaged in a never-ending quest to get more effective, safer therapies to patients in a faster and more accessible manner. They are constantly looking for ways to innovate, whether that’s exploring new drug classes for rare diseases or creatively connecting with audiences to enhance equity across communities in need. But there are […]
RWD and GenAI: How technology’s new power couple will revolutionize life sciences
Generative AI (GenAI) is quickly proving itself to be one of the most transformative technologies of our time with its ability to synthesize data and create new content as well as (or sometimes better than) its human creators. But GenAI needs a powerful partner if it’s going to wow users with high-quality, trustworthy, bias-free results: […]
COTA and Hackensack Meridian Health at ASCO 2024
Compared to information from clinical trials, real-world data (RWD) provides oncologists and cancer researchers with data on how diverse groups of patients are treated in current clinical practice. Researchers from Hackensack Meridian Health and COTA teamed up to analyze real-world treatment outcomes for people with multiple myeloma – a type of blood cancer. The findings, […]
Introducing CAILIN: The Latest Development from COTA’s AI Lab
At COTA, we know that high-quality oncology real-world data (RWD) holds the keys to the next breakthrough in cancer care. Through our work with life sciences partners, oncologists, and hospitals across the U.S., we’ve seen firsthand how data can power discoveries about new treatments and inform the right steps in care for patients. We also […]
COTA, Baptist Health South Florida, and PreciseDx Announce Collaboration on the AI-Enabled Breast Cancer Recurrence Risk Assessment, PreciseBreast™
COTA, PreciseDx and Baptist Health South Florida announced a collaboration to assess and validate the performance of the artificial intelligence (AI) -enabled PreciseBreast™ (PDxBr) test that predicts the likelihood of invasive breast cancer (IBC) recurrence.
Real-world data is helping to fine-tune care decisions for multiple myeloma patients: New research published at 2024 ASCO Annual Meeting
Researchers and clinicians agree that standards of care should be regularly reviewed and optimized based on the latest evidence to ensure that existing recommendations remain relevant.
Exploring standards of care in real-world settings with RWD
Real-world data (RWD) can help to illuminate patterns in therapy selection and the correlation to outcomes, giving oncologists and researchers some additional guidance on emerging trends in the oncology community.
From Data to Discovery: How AI Is Accelerating Progress in Oncology
the latest wave of data, technology, and artificial intelligence (AI) advances are challenging views, empowering individuals across life sciences functions to answer research questions using many different types of RWD
How COTA & Komodo Health Combine Real-World Datasets for Better Patient Insights
Komodo Health and COTA teamed up to link COTA’s high-quality oncology data with Komodo’s vast Healthcare MapTM
